You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

25 Results
Regimen
Regimen
Intent: Palliative, Adjuvant
Nov 2017
Regimen
Cancer Type:
Gynecologic, 
Germ Cell
Intent: Adjuvant
Nov 2017
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
ODB - General Benefit (with Therapeutic Notes)
    procarbazine
ODB - General Benefit
    prednisone
Nov 2017
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Nov 2017
Statistical Reports
Regimen
Regimen
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Jan 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Jan 2025
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma
Jan 2025

Pages